Merrimack completes patient enrollment in Phase 3 MM-398 study


Merrimack Pharmaceuticals (MACK) says it has reached its patient enrollment goal for a Phase 3 study of "MM-398, with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in patients with metastatic pancreatic cancer previously treated with gemcitabine-based therapy." (PR)

See more on MM-398 here.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs